Sarah Wells Kocsis, MBA, is co-author of the Milken Institute report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.” She spoke to The American Journal of Managed Care® about the findings of the report and how they can be incorporated into care for patients with chronic kidney disease (CKD).
Sarah Wells Kocsis, MBA, director of the Center for Public Health at the Milken Institute, talks about improving detection and management in chronic kidney disease (CKD) care in her recently authored report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.”
Transcript
What are the most important ways that earlier detection and management can be improved for CKD?
Well, if we were to step back and really approach this and ask, "What would this look like in an ideal world," we would really want to have a robust infrastructure that's conducive to upstream and prevention approaches—and we don't have that right now. So we're going to have to tackle this with a multi-faceted approach.
The first thing we need to do is build and have a strong foundation. The report calls out 4 large-scale areas, and they're around driving system-level change. What do I mean by that? Talking about building and sustaining a diverse workforce in community health. I'm talking about funding gaps that need to be addressed in order to support a robust infrastructure. Talking about public health data collection and surveillance and just the broader public health infrastructure.
Second, we need to capitalize on opportunities and areas with the greatest potential for impact and change. The report then kind of moves into, "What are those opportunities?" We prioritized 8 of them, and we were able to develop 40 actionable recommendations and steps for catalyzing change around those 8 opportunities.
Then lastly, big problems call for creative approaches, and we need everyone engaged. And so that's why the report also identifies and calls on 6 different stakeholder groups that we need to stand up to galvanize the movement that's needed.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More